Palbociclib

AP>99%  阿维巴坦中间体

2'-氟-2'-脱氧尿苷

ChemExpress have received EIR with the conclusion of the inspection, no FDA 483, Observations, was issued by US FDA on August 8th.

Founded in 2006, ChemExpress focuses on providing small molecule and new modalities CDMO services for both pharmaceutical and biotech clients. Our comprehensive CRO & CDMO platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs and drug products. We are a one-stop service platform to support our client’s projects from early drug discovery, process development to commercialization.